Zhen Siow

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

Sheau W Lok, James R Whittle, Francois Vaillant, Charis E Teh, Louisa L Lo, Antonia N Policheni, Alice RT Bergin, Jayesh Desai, Sarah Ftouni, Luke C Gandolfo, Danny Liew, He K Liu, G Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W Roberts, Mark A Rosenthal, Kylie Shackleton, Maria Joao Silva, et al.

Journal article  |  2019  |  CANCER DISCOVERY

Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast c..

Spotlight on the utility of the Oncotype DX (R) breast cancer assay

Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann

Journal article  |  2018  |  INTERNATIONAL JOURNAL OF WOMENS HEALTH

The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients wi..